Pharmaceuticals

Global Pneumococcal Vaccine Market Report 2026–2030: Data-Driven Growth Insights

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pneumococcal vaccine market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Pneumococcal Vaccine Market from 2026 to 2030?

The size of the pneumococcal vaccine market has shown vigorous expansion over recent years. This market is projected to expand from $9.4 billion in 2025 to $9.94 billion by 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The historical growth can be linked to several contributing factors: a significant prevalence of childhood pneumonia, their incorporation into national immunization schedules, robust endorsement from international health bodies, heightened recognition of invasive pneumococcal disease, and the established effectiveness of PCV vaccines.

The pneumococcal vaccine market size is anticipated to experience substantial expansion over the coming years. It is projected to reach $12.76 billion by 2030, showing a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period can be attributed to several factors, including the introduction of advanced PCV vaccines, wider recommendations for adult vaccination, improved access to healthcare in developing nations, growing worries about antimicrobial resistance, and governmental support for preventative immunization efforts. Key trends anticipated in this period encompass the development of conjugate vaccines for a broader range of serotype protection, a heightened emphasis on vaccination initiatives for children and the elderly, the increasing integration of combination and booster vaccination approaches, stronger collaborations between public and private sectors for wider immunization coverage, and an overall increase in preventive healthcare practices and national immunization schedules.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Drivers Are Affecting Demand In The Pneumococcal Vaccine Market?

The escalating occurrence of pneumococcal contamination is projected to propel the growth of the pneumococcal vaccine market moving forward. Pneumococcal contamination refers to any infection caused by Streptococcus pneumoniae bacteria, or pneumococcus, which can manifest as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine functions by encouraging the body to create antibodies against these bacteria, thus reducing or destroying disease-carrying pathogens and toxins to safeguard children, the elderly, and individuals with weakened immune systems from various pneumococcal infections. For example, in July 2025, an independent not-for-profit charity based in Australia, the Immunisation Coalition, observed a steady increase in cases of invasive pneumococcal disease (IPD) annually, rising from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. This increasing prevalence of pneumococcal contamination is therefore a significant driver for the growth of the pneumococcal vaccine market.

Which Segment Groups Are Influencing The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

How Are New Market Trends Shaping The Landscape Of The Pneumococcal Vaccine Market?

Key players in the pneumococcal vaccine market are introducing innovative products to enhance their profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, unveiled the V116 vaccine. V116 is designed to target the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Compared to existing pneumococcal vaccines, V116 has exhibited improved immunogenicity across various serotypes in adult populations and has also generated positive immune responses in both individuals new to vaccination and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is presently undergoing Phase 3 development.

Who Are The Primary Competitors In The Global Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pneumococcal Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795